Bristol-Myers Squibb Company (BMY) : Thursdays money flow points at investors jumping to buy the stock on the weakness of price. $38.54 million worth of transactions were on upticks, whereas, the downticks accounted for $33.92 million worth of transactions. The net money flow was a positive $4.62 million and the uptick to downtick ratio was 1.14. However, the block trades showed a clear dominance of the bulls with a very healthy ratio of 4.63 in their favor. The net money flow into the stock was $6.02 million. The value of block trades done on downticks was only $1.66 million. The lack of interest in trading on downticks shows that the investors dont want to sell their holdings. The upticks accounted for $7.68 million of the total block trades, indicating continued buying interest on weakness, which bodes well for the future of the stock. Bristol-Myers Squibb Company (BMY) was trading at $76.49, down $0.09 during day. The stock slid -0.12% over the previous days close. For the week, the stock recorded 1.61% over the previous weeks close.
The stock has recorded a 20-day Moving Average of 5.4% and the 50-Day Moving Average is 6.68%. Shares have rallied 7.61% from its 1 Year high price. On Jul 11, 2016, the shares registered one year high at $75.84 and the one year low was seen on Aug 24, 2015. The 50-Day Moving Average price is $72.47 and the 200 Day Moving Average price is recorded at $67.35.
Bristol-Myers Squibb Company (NYSE:BMY): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $76.79 and $76.29 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $76.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $76.77, notching a gain of 0.25% for the day. The total traded volume was 4,352,625 . The stock had closed at $76.58 on the previous day.
In an insider trading activity, Andreotti Lamberto, Director of BRISTOL MYERS SQUIBB CO, unloaded 23,200 shares at an average price of $72.31 on June 28, 2016. The total amount of the transaction was worth $1,677,592, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.